Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Selley

Showing results (131-140 of 149) with videos related to

Pageof 15
Sort By:
Nature Neuroscience|January 18, 2006
An essential role for DeltaFosB in the nucleus accumbens in morphine actionVenetia Zachariou, Carlos A Bolanos, Dana E Selley, et al.
Nature Chemical Biology|November 26, 2008
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effectsJonathan Z Long, Weiwei Li, Lamont Booker, et al.
ACS Chemical Neuroscience|February 14, 2019
Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder TreatmentSamuel Obeng, Abdulmajeed Jali, Yi Zheng, et al.
Journal of Medicinal Chemistry|May 30, 2024
Systematic Structure-Activity Relationship Study of Nalfurafine Analogues toward Development of Potentially Nonaddictive Pain Management TreatmentsCelsey M St Onge, Piyusha P Pagare, Yi Zheng, et al.
Molecules (Basel, Switzerland)|October 14, 2022
A Journey through Diastereomeric Space: The Design, Synthesis, In Vitro and In Vivo Pharmacological Activity, and Molecular Modeling of Novel Potent Diastereomeric MOR Agonists and AntagonistsDana R Chambers, Agnieszka Sulima, Dan Luo, et al.
Molecular Pharmacology|November 30, 2016
Cannabinoid Receptor Interacting Protein 1a Competition with β-Arrestin for CB1 Receptor Binding SitesLawrence C Blume, Theresa Patten, Khalil Eldeeb, et al.
Journal of Medicinal Chemistry|November 3, 2012
Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor AgentsYunyun Yuan, Orgil Elbegdorj, Jianyang Chen, et al.
ACS Chemical Neuroscience|May 20, 2025
Transformation of a Potent C9-Substituted Phenylmorphan into MOR Partial Agonists with Improvement of Metabolic Stability: An In Vitro, In Vivo, and In Silico StudyDelmis E Hernandez, Dan Luo, Thomas E Prisinzano, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 23, 2015
Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in MiceSudeshna Ghosh, Steven G Kinsey, Qing-Song Liu, et al.
Synapse (New York, N.Y.)|February 23, 2008
Distinct patterns of DeltaFosB induction in brain by drugs of abuseL I Perrotti, R R Weaver, B Robison, et al.
Pageof 15

Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
Nature Neuroscience|January 18, 2006
An essential role for DeltaFosB in the nucleus accumbens in morphine actionVenetia Zachariou, Carlos A Bolanos, Dana E Selley, et al.
Nature Chemical Biology|November 26, 2008
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effectsJonathan Z Long, Weiwei Li, Lamont Booker, et al.
ACS Chemical Neuroscience|February 14, 2019
Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder TreatmentSamuel Obeng, Abdulmajeed Jali, Yi Zheng, et al.
Journal of Medicinal Chemistry|May 30, 2024
Systematic Structure-Activity Relationship Study of Nalfurafine Analogues toward Development of Potentially Nonaddictive Pain Management TreatmentsCelsey M St Onge, Piyusha P Pagare, Yi Zheng, et al.
Molecules (Basel, Switzerland)|October 14, 2022
A Journey through Diastereomeric Space: The Design, Synthesis, In Vitro and In Vivo Pharmacological Activity, and Molecular Modeling of Novel Potent Diastereomeric MOR Agonists and AntagonistsDana R Chambers, Agnieszka Sulima, Dan Luo, et al.
Molecular Pharmacology|November 30, 2016
Cannabinoid Receptor Interacting Protein 1a Competition with β-Arrestin for CB1 Receptor Binding SitesLawrence C Blume, Theresa Patten, Khalil Eldeeb, et al.
Journal of Medicinal Chemistry|November 3, 2012
Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor AgentsYunyun Yuan, Orgil Elbegdorj, Jianyang Chen, et al.
ACS Chemical Neuroscience|May 20, 2025
Transformation of a Potent C9-Substituted Phenylmorphan into MOR Partial Agonists with Improvement of Metabolic Stability: An In Vitro, In Vivo, and In Silico StudyDelmis E Hernandez, Dan Luo, Thomas E Prisinzano, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 23, 2015
Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in MiceSudeshna Ghosh, Steven G Kinsey, Qing-Song Liu, et al.
Synapse (New York, N.Y.)|February 23, 2008
Distinct patterns of DeltaFosB induction in brain by drugs of abuseL I Perrotti, R R Weaver, B Robison, et al.
Pageof 15